- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04433065
TTVR tidig genomförbarhetsstudie
Den tidiga genomförbarhetsstudien av Transkateter Tricuspid Valve Replacement System Transfemoral System
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Multi-center, prospective, non-randomized, investigational, and pre-market.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- University of Alabama at Birmingham (UAB) Hospital
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85016
- Abrazo Arizona Heart Hospital
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Cedars Sinai Medical Center
-
San Francisco, California, Förenta staterna, 94115
- California Pacific Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06102
- Hartford Hospital
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30308
- Emory University Hospital Midtown
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Health System - University Hospital
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Corewell Health
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55407
- Abbott Northwestern Hospital
-
-
Montana
-
Missoula, Montana, Förenta staterna, 59802
- Providence Saint Patrick Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10029
- The Mount Sinai Hospital
-
New York, New York, Förenta staterna, 10032
- New York-Presbyterian Hospital Columbia University Medical Center
-
The Bronx, New York, Förenta staterna, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45242
- The Christ Hospital
-
Cleveland, Ohio, Förenta staterna, 44106
- University Hospitals Cleveland Medical Center
-
Columbus, Ohio, Förenta staterna, 43214
- OhioHealth Riverside Methodist Hospital
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Oregon Health & Science University Hospital
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, Förenta staterna, 17101
- UPMC Pinnacle Harrisburg Campus
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Houston Methodist Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53125
- Aurora Saint Lukes Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Heart Team agrees that patient is deemed symptomatic despite medical therapy (including obligatory diuretic) and a candidate for bioprosthetic tricuspid valve replacement
- Subject is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the local Heart Team
- Subjects with severe symptomatic primary and / or secondary tricuspid regurgitation determined by the Echocardiography Core Lab assessment of a qualifying transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE)
- New York Heart Association (NYHA) Function Class II or greater
- Subject anatomically suitable for the Intrepid TTVR delivery system including transfemoral access
- Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
- Subject meets the legal minimum age to provide informed consent based on local regulatory requirements
Exclusion Criteria:
- Estimated life expectancy of less than 24 months due to associated non-cardiac co-morbid conditions
- Anatomic contraindications for Intrepid™ TTVR (e.g., annular dimensions)
- Evidence of intracardiac mass, inferior vena cava, or femoral venous mass or thrombus
- Implanted with venous stents (iliac and/or femoral) or inferior vena cava (IVC) filter or congenital abnormalities of the IVC that would preclude ability for transfemoral access of delivery system
- Echocardiographic evidence of severe right ventricular dysfunction
- Left ventricular ejection fraction (LVEF) <30 as measured by resting echocardiogram within 30 days of the Index Procedure
- Need for emergent or urgent surgery
- Untreated clinically significant coronary artery disease requiring revascularization
- Carcinoid tricuspid regurgitation
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Primary Cohort
Device: Intrepid TTVR System |
Device: Intrepid™ TTVR System |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of implant or delivery related serious adverse events
Tidsram: Through 30 days post-procedure
|
Rate of implant or delivery related serious adverse events |
Through 30 days post-procedure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Successful access, delivery of implant, and retrieval of the delivery system assessed by definitions per Mitral Valve Academic Research Consortium (MVARC)
Tidsram: During Procedure
|
For procedural success to be present, device success must have been achieved without major clinical complications as detailed per clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement (part 2: endpoint definitions) |
During Procedure
|
|
Change in TR Grade from baseline
Tidsram: Through 30 days post-procedure
|
Change in TR Grade from baseline |
Through 30 days post-procedure
|
|
Rate of no significant TV stenosis
Tidsram: Through 30 days post-procedure
|
Rate of no significant TV stenosis |
Through 30 days post-procedure
|
|
Change in NYHA Class from baseline
Tidsram: Through 30 days post-procedure
|
Change in NYHA Class from baseline |
Through 30 days post-procedure
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MDT20009TMV003
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .